Literature DB >> 22527853

T-cell prolymphocytic leukemia in Japan: is it a variant?

Junichi Kameoka1, Naoto Takahashi, Hideyoshi Noji, Kazunori Murai, Katsushi Tajima, Yoshihiro Kameoka, Shinji Sato, Tsutomu Shichishima, Yoji Ishida, Hideo Harigae, Kenichi Sawada.   

Abstract

T-cell prolymphocytic leukemia (T-PLL) is characterized by a post-thymic immunophenotype, salient chromosome abnormalities, and an aggressive clinical course. However, cases in which these features are absent have been occasionally reported in Japan. Here, clinical and biological features of 13 T-PLL cases, diagnosed between 1992 and 2009 in the Tohoku region of Japan, were compared with three Western series. Median age was 64 (range 40-78) years old, and the male to female ratio (12:1) was higher than that of the Western series (P < 0.04). Presented manifestations were similar to those of Western cases, but central nervous system involvement, which is rare in Western cases, was observed in 3 of 13 cases (23 %) (P < 0.04). Immunophenotypic patterns were similar to those of Western cases, but HLA-DR was positive in 6 of 9 cases (67 %), which is distinct from Western cases (0-9 %) (P < 0.002). By chromosome analyses, 14q11 abnormality and trisomy 8q, which are common among Western cases (70-80 %), were not observed in any cases (P < 0.002). Morphologically, seven were classified as typical type, five as a small-cell variant, and one as a cerebriform variant. Seven cases experienced an aggressive course, whereas six experienced an indolent course over a median follow-up of 50 months. In contrast to Western cases, clinical courses were closely correlated with morphological types; 86 % of typical types were aggressive, whereas 83 % of small-cell types were indolent (P = 0.025). On the basis of these observations, together with previous Japanese cases in the literature, we propose that Japanese cases of T-PLL may constitute a variant.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22527853     DOI: 10.1007/s12185-012-1077-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  29 in total

1.  Production of vascular endothelial growth factor in T-cell prolymphocytic leukemia.

Authors:  Toshie Ogasawara; Chisako Narita; Kiyotaka Kawauchi
Journal:  Leuk Res       Date:  2006-04-18       Impact factor: 3.156

2.  T-cell prolymphocytic leukemia involving extramedullary sites.

Authors:  Jose R Valbuena; Marco Herling; Joan H Admirand; Anthony Padula; Dan Jones; L Jeffrey Medeiros
Journal:  Am J Clin Pathol       Date:  2005-03       Impact factor: 2.493

3.  [Successful treatment of T-cell prolymphocytic leukemia (T-PLL) with fludarabine monophosphate].

Authors:  Akinori Maeda; Kazuya Iwai; Takafumi Ishibashi
Journal:  Rinsho Ketsueki       Date:  2009-08

4.  Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Français d'Hématologie Cellulaire.

Authors:  R Garand; J Goasguen; A Brizard; J Buisine; A Charpentier; J F Claisse; E Duchayne; M Lagrange; C Segonds; X Troussard; G Flandrin
Journal:  Br J Haematol       Date:  1998-11       Impact factor: 6.998

5.  A case of T cell prolymphocytic leukemia involving blast transformation.

Authors:  Kunimoto Ichikawa; Masaaki Noguchi; Hidenori Imai; Yasunobu Sekiguchi; Mutsumi Wakabayashi; Tomohiro Sawada; Norio Komatsu
Journal:  Int J Hematol       Date:  2011-04-21       Impact factor: 2.490

6.  [Unclassified mature T cell leukemia with cerebriform nuclei].

Authors:  Makiko Takizawa; Takafumi Matsushima; Akihiko Yokohama; Hiroshi Handa; Norifumi Tsukamoto; Masamitsu Karasawa; Hirokazu Murakami; Yoshihisa Nojima
Journal:  Rinsho Ketsueki       Date:  2005-07

7.  Chromosome abnormalities in adult T-cell leukemia/lymphoma: a karyotype review committee report.

Authors:  N Kamada; M Sakurai; K Miyamoto; I Sanada; N Sadamori; S Fukuhara; S Abe; Y Shiraishi; T Abe; Y Kaneko
Journal:  Cancer Res       Date:  1992-03-15       Impact factor: 12.701

8.  High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia.

Authors:  Marco Herling; Kaushali A Patel; Michael A Teitell; Marina Konopleva; Farhad Ravandi; Ryuji Kobayashi; Dan Jones
Journal:  Blood       Date:  2007-09-21       Impact factor: 22.113

Review 9.  CD3-negative, CD20-positive T-cell prolymphocytic leukemia: case report and review of the literature.

Authors:  Kenji Tamayose; Naotake Sato; Jun Ando; Koichi Sugimoto; Kazuo Oshimi
Journal:  Am J Hematol       Date:  2002-12       Impact factor: 10.047

Review 10.  Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper.

Authors:  M Dungarwalla; E Matutes; C E Dearden
Journal:  Eur J Haematol       Date:  2008-03-10       Impact factor: 2.997

View more
  1 in total

1.  Modified Hyper-CVAD Regimen Followed by Autologous Peripheral Blood Stem Cell Transplantation Successfully Treated Synchronous T-Cell Prolymphocytic Leukemia and Gastric Cancer in a 68-Year-Old Female.

Authors:  Guangquan Zhou; Bai He; Tongbing Chen; Jiannong Cen; Yang Cao; Weiying Gu
Journal:  Indian J Hematol Blood Transfus       Date:  2016-11-24       Impact factor: 0.900

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.